Pancreatic CancerSPLENDID RCTNCT07799298
Spleen Preservation Versus Splenectomy in Left Pancreatectomy for Pancreatic Ductal Adenocarcinoma (SPLENDID)
A study testing SPLP and LPS in people with Pancreatic Cancer and Pancreatectomy, run by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) at 1 site in Netherlands.
Trial summary
Rationale: During left pancreatectomy for pancreatic ductal adenocarcinoma (PDAC), routine en-bloc splenectomy is performed to achieve complete nodal clearance of the splenic hilum. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Pancreatic Cancer, Pancreatectomy, Adenocarcinoma Pancreas
- What is being tested?
- SPLP and LPS
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 360 participants
- Where
- 1 siteNetherlands
- Study dates
- 1 Nov 2026to 1 Nov 2034
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age at least 18 years;
- Elective indication for left pancreatectomy for proven or suspected PDAC;
- Upfront resectable or borderline-resectable PDAC in the pancreatic neck, body or tail, according to the National Comprehensive Cancer Network® (NCCN®);
- o Patients receiving neo-adjuvant treatment can be included in the trial, if the tumor was upfront resectable or borderline-resectable before the start of neoadjuvant therapy. Patients receiving induction therapy for locally advanced pancreatic cancer (LAPC) will be excluded.
- Spleen preservation using SPLP with the Warshaw (splenic vessel-resecting) procedure including Gerota's fascia (i.e. circumferentially radical) is feasible according to the local treatment team;
- Fit to undergo left pancreatectomy according to the surgeon and anesthesiologist;
- Written informed consent.
Who cannot join
- Preoperative imaging indicating (possible) tumor involvement of the perisplenic LNs (LN station 10 and perisplenic fat);
- Distance between the left border of the tumor and the center of the splenic hilum is <3cm on preoperative imaging;
- Locally advanced PDAC according to the NCCN definition or distant metastasis;
- Previous abdominal surgery in which the short gastric and/or left gastroepiploic vessels were ligated (e.g. gastrectomy, gastric sleeve, fundoplication), resulting in the impossibility of performing a Warshaw (spleen-vessel resecting) procedure;
- Pregnancy.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Charlotte Baggerman van Houweninge, MD contact
About this study
Official title: Spleen Preservation Versus Splenectomy in Left Pancreatectomy for Pancreatic Ductal Adenocarcinoma (SPLENDID): an International Randomized Controlled Trial
Rationale: During left pancreatectomy for pancreatic ductal adenocarcinoma (PDAC), routine en-bloc splenectomy is performed to achieve complete nodal clearance of the splenic hilum. However, evidence that splenectomy improves survival is lacking, while splenectomy may increase postoperative morbidity and has lifelong consequences related to loss of splenic function. Spleen-preserving left pancreatectomy (SPLP) may be a safe alternative, but high-quality evidence is lacking.
Objective: To compare SPLP with left pancreatectomy with splenectomy (LPS) regarding overall survival and major postoperative morbidity in patients with resectable or borderline resectable PDAC.
Read more
Study design: An international, randomized, controlled, multicenter, non-inferiority trial.
Study population: Two groups of 180 patients (360 in total) with proven or suspected resectable or borderline resectable PDAC requiring left pancreatectomy.
Intervention: Spleen-preserving left pancreatectomy (SPLP)
Control: Left pancreatectomy with splenectomy (LPS)
Read the detailed description
Rationale: During left pancreatectomy for pancreatic ductal adenocarcinoma (PDAC), routine en-bloc splenectomy is performed to achieve complete nodal clearance of the splenic hilum. However, there is no evidence that routine splenectomy improves survival. Splenectomy has been associated with increased postoperative morbidity, lifelong vaccination requirements, and risk of overwhelming post-splenectomy infection. In addition, lymph node metastases in the splenic hilum are uncommon (~4%), and preservation of splenic immune function is becoming increasingly important with the emergence of novel immunotherapies. Spleen-preserving left pancreatectomy (SPLP) may therefore be a safe alternative to routine splenectomy, but no randomized trials have evaluated this approach.
Objective: To compare SPLP with left pancreatectomy with splenectomy (LPS) regarding (1) overall survival over a 3-year period, assessed using restricted mean survival time (RMST), and (2) major postoperative complications within 90 days (Clavien-Dindo grade III or higher) in patients with resectable or borderline resectable PDAC.
Study design: An international randomized multicenter non-inferiority trial performed in high-volume pancreatic centers. Participating centers perform at least 15 left pancreatectomies annually, and participating surgeons have completed at least 30 SPLPs (for any indication) and 15 left pancreatectomies for PDAC. Randomization will be performed in a 1:1 ratio using a secure web-based system, stratified for receipt of neoadjuvant therapy (yes/no) and tumor location (body/neck versus tail).
Study population: Two groups of 180 patients (360 in total) with proven or suspected resectable or borderline resectable PDAC requiring left pancreatectomy.
Intervention: Spleen-preserving left pancreatectomy.
Control: Left pancreatectomy with splenectomy.
Main study parameters/endpoints: The primary endpoint is overall survival over a 3-year period, assessed using RMST. The main secondary endpoint is major postoperative morbidity within 90 days (Clavien-Dindo grade III or higher). Other secondary outcomes include quality of life, R0 resection rate, disease-free survival, time to and site of recurrence, receipt, timing and completion of adjuvant therapy, pancreas-specific and general postoperative complications, unplanned splenectomy in the SPLP group, secondary splenectomy, spleen- and asplenia-related complications, time to functional recovery, length of hospital stay, health-care resource utilization, and cost-effectiveness.
- Conditions
- Pancreatic Cancer, Pancreatectomy, Adenocarcinoma Pancreas
- Being tested
- SPLP, LPS
- Keywords
- Left pancreatectomy, Pancreatic Cancer, Spleen-preservation, Warshaw procedure, Splenectomy
- Medical subject headings
- Pancreatic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SPLPProcedure or surgery
Spleen-preserving Left Pancreatectomy
LPSProcedure or surgery
Left Pancreatectomy with Splenectomy
| Study group | Role | What they receive |
|---|---|---|
| Spleen-preservation | Experimental | Not described Receives: Procedure: SPLP |
| Splenectomy | Active comparator | Not described Receives: Procedure: LPS |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall survival over a 3-year time period (3-year restricted mean survival time (RMST))
Measured: Until 3-years after the day of surgery
Secondary outcomes (1)
90-day major postoperative complications
Clavien-Dindo classification grade ≥3
Measured: From the day of surgery until 90-days postoperative
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Sep 2026
- Study start1 Nov 2026 (estimated)
- Primary completion1 Nov 2032 (estimated)
- Study completion1 Nov 2034 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pancreatic CancerStudies of the same condition, open and under way.
- More trials run by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 360 participants (estimated)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, M.G. Besselink, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Investigators
- Jony van Hilst, MD, PhD, Principal investigator, Amsterdam UMCMarc G. Besselink, MD, PhD, Principal investigator, Amsterdam UMCMohammad Abu Hilal, MD, PhD, Principal investigator, Jordan University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07799298
- Sponsor's protocol ID
- NL.012057
- Acronym
- SPLENDID RCT
- Status last verified
- Aug 2026
- First submitted
- 31 Jul 2026
- Last updated
- 2 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 2 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Spleen Preservation Versus Splenectomy in Left Pancreatectomy for Pancreatic Ductal Adenocarcinoma (SPLENDID): an International Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT07799298
- Acronym / sponsor ID
- SPLENDID RCT / NL.012057
- Conditions
- Pancreatic Cancer, Pancreatectomy, Adenocarcinoma Pancreas
- Keywords
- Left pancreatectomy, Pancreatic Cancer, Spleen-preservation, Warshaw procedure, Splenectomy
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 360 participants (estimated)
- Lead sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)University, hospital or other
- Study start
- 1 Nov 2026 (estimated)
- Primary completion
- 1 Nov 2032 (estimated)
- Study completion
- 1 Nov 2034 (estimated)
- First posted
- 2 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Rationale: During left pancreatectomy for pancreatic ductal adenocarcinoma (PDAC), routine en-bloc splenectomy is performed to achieve complete nodal clearance of the splenic hilum. However, evidence that splenectomy improves survival is lacking, while splenectomy may increase postoperative morbidity and has lifelong consequences related to loss of splenic function. Spleen-preserving left pancreatectomy (SPLP) may be a safe alternative, but high-quality evidence is lacking.
Objective: To compare SPLP with left pancreatectomy with splenectomy (LPS) regarding overall survival and major postoperative morbidity in patients with resectable or borderline resectable PDAC.
Study design: An international, randomized, controlled, multicenter, non-inferiority trial.
Study population: Two groups of 180 patients (360 in total) with proven or suspected resectable or borderline resectable PDAC requiring left pancreatectomy.
Intervention: Spleen-preserving left pancreatectomy (SPLP)
Control: Left pancreatectomy with splenectomy (LPS)
Detailed description
Rationale: During left pancreatectomy for pancreatic ductal adenocarcinoma (PDAC), routine en-bloc splenectomy is performed to achieve complete nodal clearance of the splenic hilum. However, there is no evidence that routine splenectomy improves survival. Splenectomy has been associated with increased postoperative morbidity, lifelong vaccination requirements, and risk of overwhelming post-splenectomy infection. In addition, lymph node metastases in the splenic hilum are uncommon (~4%), and preservation of splenic immune function is becoming increasingly important with the emergence of novel immunotherapies. Spleen-preserving left pancreatectomy (SPLP) may therefore be a safe alternative to routine splenectomy, but no randomized trials have evaluated this approach.
Objective: To compare SPLP with left pancreatectomy with splenectomy (LPS) regarding (1) overall survival over a 3-year period, assessed using restricted mean survival time (RMST), and (2) major postoperative complications within 90 days (Clavien-Dindo grade III or higher) in patients with resectable or borderline resectable PDAC.
Study design: An international randomized multicenter non-inferiority trial performed in high-volume pancreatic centers. Participating centers perform at least 15 left pancreatectomies annually, and participating surgeons have completed at least 30 SPLPs (for any indication) and 15 left pancreatectomies for PDAC. Randomization will be performed in a 1:1 ratio using a secure web-based system, stratified for receipt of neoadjuvant therapy (yes/no) and tumor location (body/neck versus tail).
Study population: Two groups of 180 patients (360 in total) with proven or suspected resectable or borderline resectable PDAC requiring left pancreatectomy.
Intervention: Spleen-preserving left pancreatectomy.
Control: Left pancreatectomy with splenectomy.
Main study parameters/endpoints: The primary endpoint is overall survival over a 3-year period, assessed using RMST. The main secondary endpoint is major postoperative morbidity within 90 days (Clavien-Dindo grade III or higher). Other secondary outcomes include quality of life, R0 resection rate, disease-free survival, time to and site of recurrence, receipt, timing and completion of adjuvant therapy, pancreas-specific and general postoperative complications, unplanned splenectomy in the SPLP group, secondary splenectomy, spleen- and asplenia-related complications, time to functional recovery, length of hospital stay, health-care resource utilization, and cost-effectiveness.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Spleen-preservation | Experimental | Procedure: SPLP |
| Splenectomy | Active comparator | Procedure: LPS |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Age at least 18 years;
- Elective indication for left pancreatectomy for proven or suspected PDAC;
- Upfront resectable or borderline-resectable PDAC in the pancreatic neck, body or tail, according to the National Comprehensive Cancer Network® (NCCN®);
- o Patients receiving neo-adjuvant treatment can be included in the trial, if the tumor was upfront resectable or borderline-resectable before the start of neoadjuvant therapy. Patients receiving induction therapy for locally advanced pancreatic cancer (LAPC) will be excluded.
- Spleen preservation using SPLP with the Warshaw (splenic vessel-resecting) procedure including Gerota's fascia (i.e. circumferentially radical) is feasible according to the local treatment team;
Key exclusion criteria (5 listed)
- Preoperative imaging indicating (possible) tumor involvement of the perisplenic LNs (LN station 10 and perisplenic fat);
- Distance between the left border of the tumor and the center of the splenic hilum is <3cm on preoperative imaging;
- Locally advanced PDAC according to the NCCN definition or distant metastasis;
- Previous abdominal surgery in which the short gastric and/or left gastroepiploic vessels were ligated (e.g. gastrectomy, gastric sleeve, fundoplication), resulting in the impossibility of performing a Warshaw (spleen-vessel resecting) procedure;
- Pregnancy.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SPLPSpleen-preserving Left Pancreatectomy | Procedure or surgery | Spleen-preservation |
| LPSLeft Pancreatectomy with Splenectomy | Procedure or surgery | Splenectomy |
Primary outcome
Overall survival over a 3-year time period (3-year restricted mean survival time (RMST))
Time frame: Until 3-years after the day of surgery
1 secondary outcome
90-day major postoperative complications
Time frame: From the day of surgery until 90-days postoperative
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Sep 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Pancreatic Cancer
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
RecruitingPhase 2/3
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
Oesophageal Cancer, Gastric Cancer
RecruitingPhase 1
Modified FOLFIRINOX and Pentamidine in Advanced and Metastatic Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma (PDAC)
RecruitingPhase 3
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Pancreatic Cancer, Pancreatic Cancer Metastatic
RecruitingPhase 3
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
Pancreatic Carcinoma, Pancreatic Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Charlotte Baggerman van Houweninge, MD contact
Jony van Hilst, MD, PhD principal investigator
Amsterdam UMC
Marc G. Besselink, MD, PhD principal investigator
Amsterdam UMC
Mohammad Abu Hilal, MD, PhD principal investigator
Jordan University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing SPLP and LPS in people with Pancreatic Cancer and Pancreatectomy, run by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) at 1 site in Netherlands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 2 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Charlotte Baggerman van Houweninge, MD (031 020 444 4444, c.e.baggermanvanhouweninge@amsterdamumc.nl), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall survival over a 3-year time period (3-year restricted mean survival time (RMST)) (time frame: Until 3-years after the day of surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Sep 2026.